Drug intelligence / Profile preview

GWZ003

Development stage: Preclinical
Lead developer: Ginwa Enterprise Group
Administration: Oral

Overview

GWZ003 is an innovative traditional Chinese medicine (TCM) candidate, classified as TCM Class 1.1, developed by GINWA Pharmaceutical Factory. It is formulated as oral granules and is intended for the treatment of chronic kidney disease (CKD). The project has received clinical trial approval (IND) in China, indicating it is transitioning from preclinical research to clinical evaluation. As a Class 1.1 TCM, it represents a novel formulation or a new therapeutic application of traditional ingredients that has not been previously approved for marketing.

Beyond the preview

Go deeper on GWZ003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GWZ003.

Explore the full profile